Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...